Aimei Health Technology Co., Ltd
NASDAQ:AFJKShell Companies
-$3.66 today
- Market cap
- $73.22M
- Beta
- 0.23
- P/E (TTM)
- 34.3
- EPS (TTM)
- $0.88
Volume 0.13M
Average 0.02M
AFJK Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Aimei Health Technology Co., LtdNASDAQ: AFJK
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q1 FY2026 short-term investments was $0, compared with $0 a year earlier.
Context
- Short-term investments amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Short-term investments increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Short-term Investments vs competitors
How AFJK compares with its peers on the latest reported figures
- AFJK's Mar 2026 short-term investments of $0 is the 3rd highest of the 8 companies compared; the peer median is $0.
- Short-term investments amounts to 0.0% of total assets for AFJK, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $58.89M | +3.3% | — | 11.0% | |
| Mar 2026 | $37.72M | — | — | 99.9% | |
AFJKAimei Health Technology Co., Ltd | Mar 2026 | $0 | — | — | 0.0% |
KOYNCSLM Digital Asset Acquisition Corp III Class A Ordinary Shares | Mar 2026 | $0 | — | — | 0.0% |
EURKEureka Acquisition Corp Class A Ordinary Share | Mar 2026 | $0 | — | — | 0.0% |
UYSCUY Scuti Acquisition Corp. | Dec 2025 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
ORIQUOrigin Investment Corp I Units | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding AFJK) | $0 | +3.3% | — | 0.0% | |
Competitors are the stored peer set for AFJK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Cash & Equivalents | 580.72K | 28.21K | 2.93K |
| Short-term Investments | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 |
| Total Current Assets | 580.72K | 30.38K | 2.93K |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-term Investments | 69.89M | 73.78M | 12.1M |
| Tax Assets | 0 | 0 | 0 |
| Other Non-current Assets | (1) | 0 | 0 |
| Total Non-current Assets | 69.89M | 73.78M | 12.1M |
| Total Assets | 70.47M | 73.81M | 12.1M |
| Account Payables | 0 | 0 | 0 |
| Short-term Debt | 0 | 227.7K | 2.02M |
| Tax Payables | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 |
| Total Current Liabilities | 24.84K | 816.99K | 3.37M |
| Long-term Debt | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 |
| Other Non-current Liabilities | 690K | 690K | 690K |
| Total Non-current Liabilities | 690K | 690K | 690K |
| Total Liabilities | 714.84K | 1.51M | 4.06M |
| Common Stock | 69.89M | 73.78M | 12.1M |
| Retained Earnings | (134.34K) | (1.48M) | (4.06M) |
| Accumulated OCI | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| Total Equity | 69.76M | 72.31M | 8.04M |
| Total Debt | 0 | 227.7K | 2.02M |
| Net Debt | (580.72K) | 199.49K | 2.02M |
Aimei Health Technology Co., Ltd
NASDAQ:AFJK
Intrinsic Alpha fair value
Locked
Current Price
$11.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.